(Total Views: 571)
Posted On: 08/23/2024 8:35:27 AM
Post# of 148863
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
Download as PDFAugust 23, 2024 8:30am EDT
VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has engaged Syneos Health as the contract research organization (“CRO”) for its upcoming Phase II study exploring leronlimab and its effects on chronic inflammation.
Syneos Health is a leading fully integrated biopharmaceutical solutions organization providing services across the drug development lifecycle to help customers accelerate the delivery of life saving therapies to market. Syneos Health has helped to develop or commercialize 92% of novel new drugs approved by the FDA in the last five years (2019-2023) and 91% of products granted marketing authorization by the European Medicines Agency.
“We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation. With the company’s support, our goal is to generate clinical data that we believe will affirm the utility of leronlimab in addressing a number of medical concerns impacting patients globally,” said Dr. Jacob Lalezari, CEO.
Download as PDFAugust 23, 2024 8:30am EDT
VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it has engaged Syneos Health as the contract research organization (“CRO”) for its upcoming Phase II study exploring leronlimab and its effects on chronic inflammation.
Syneos Health is a leading fully integrated biopharmaceutical solutions organization providing services across the drug development lifecycle to help customers accelerate the delivery of life saving therapies to market. Syneos Health has helped to develop or commercialize 92% of novel new drugs approved by the FDA in the last five years (2019-2023) and 91% of products granted marketing authorization by the European Medicines Agency.
“We are looking forward to working with Syneos Health to advance our Phase II study of leronlimab’s effects on chronic inflammation. With the company’s support, our goal is to generate clinical data that we believe will affirm the utility of leronlimab in addressing a number of medical concerns impacting patients globally,” said Dr. Jacob Lalezari, CEO.
(5)
(0)Scroll down for more posts ▼
